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EDITORIAL 
What Does Epidermal Growth Factor Do and How Does It Do It? 
In the last three years the basic research into the mechanisms 
of action of epidermal growth factor (EGF) have been unbe-
lievably productive. In this issue Aoyagi et a! [1] report that 
EGF increased release of arachidonic acid from pig skin. This 
editorial cannot answer how EGF works in exquisite detail but 
attempts to relate their findings to current concepts (for re-
views, see [2- 12]). 
What is EGF and where is it produced? Until recently EGF 
was thought of as a small, 6054 molecular weight protein, 
isolated from the submaxillary gland by Stanley Cohen . Cloned 
mouse EGF eDNA was sequenced and found to be derived from 
a very large EGF precursor containing 976 amino acids of 
130,000 daltons (for review, see [5]). Within this pre-pro-EGF 
7 EGF-like peptides were observed. Within the nucleus EGF 
was localized to chromosome 4q [13], the same region as T-cell 
growth factor [14]. Brissenden et a! [13] suggest that EGF, a-
transforming growth factor (a-TGF), and T-cell growth factor 
(interleukin II) may be a "gene family" [5]. The precise cell or 
cells of EGF production are unclear and it may be produced by 
many cells. 
What natural factors mimic the activity ofEGF? Any natural 
factor such as arachidonic acid and its metabolites and even its 
homologous protein urogastrone (cf [4]) may mimic part or all 
of EGF's effects. Therefore, more rigorous criteria for assessing 
the EGF-like properties of a compound now include the ability 
to bind to, interact with, or modulate the specific cell membrane 
receptors for EGF. For example, sarcoma growth factor (SGF) 
which is actually composed of two independent growth factors 
(a -TGF, ,B-TGF) competes for binding to specific EGF recep-
tors, but does not immunologically cross-react with ~GF [5, 
15]. a-TGF shows an overall but limited homology w1th EGF 
[16], competes with labeled EGF for binding to EGF rec~ptors, 
and mimics EGF's effects in vitro. ,8-TGF is required to mduce 
anchorage independent growth of non transformed cells by EGF 
or a-TGF in vitro and unlike a-TGF does not bind to the EGF 
receptor [5,15]. How these TGFs affect human skin or relate 
to pre-pro-EGF is not currently known. 
How does EGF directly interact with tissues? Since EGF 
affects intracellular reactions, presumably it directly modifies 
its membrane receptors to activate its endogenous tyrosine 
kinase (see below). It is now generally agreed that many peptide 
hormones such as EGF bind to their external membrane recep-
tors which cluster and internalize [5,6,12]. Ligand:receptor 
complexes are internali zed in clathrin-coated pits [12] and 
degraded within lysosomal vesic les. Some receptors recycle, 
some are degraded, and synthesis of new receptors does not 
appear to be altered [17]. No unequivocal evidence that intra-
cellular processing of EGF or its specific receptor causes or is 
necessary for generating any biologic responses is yet avai lable 
[5] . 
What is the EGF receptor and how does it transmit its 
signals? To understand how EGF "works" in molecular terms, 
the structure of the EGF receptor and what genetic factors 
control it must be defined. The EGF receptor gene is on human 
chromosome 7 [18]. Using eDNA clones from A-431 cells and 
placenta, 4 groups deduced the complete amino acid sequence 
of the human EGF receptor precursor (for review, see [11]). A 
close similarity between the entire predicted· u-erb-B mRNA 
oncogene product of the avian erythroblastosis virus and the 
EGF receptor transmembrane and cytoplasmic domain was 
noted [11], i.e., the erb b transforming protein is a truncated 
EGF receptor protein lacking the extracellular binding domain. 
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The EGF receptor-kinase molecule is a single-chain glycopro-
tein of 1186-1210 amino acids [11] and contains several func-
tional domains within its structure: an externally located EGF 
binding site of about 100,000 daltons, a single-chain transmem-
brane portion of relatively small size, and a cytoplasmic domain 
of about 60,000 daltons [11]. This cytoplasmic domain contains 
the major autophosphorylation sites, the endogenous, EGF-
stimulated tyrosine kinase activity, and a region that is 35-
90% homologous with transforming proteins from the src family 
[11] . Where the putative endonuclease [19] activity which 
directly affects DNA would be located within the EGF receptor 
is not known. When the EGF receptor is selectively degraded, 
an active 42,000 dalton protein kinase that no longer is sensitive 
to EGF is released [20]. How extracellular EGF binding regu-
lates the cytoplasmically located tyrosine kinase activity is not 
clear but may involve a specific threonine site [21]. Regulation 
of the intrinsic activities in the EGF receptor is of interest as 
they may not have the same sites of action. The nature and 
sequence of endogenous substrates which are phosphorylated 
by or phosphorylate the EGF tyrosine kinase is not yet clear. 
What does EGF do in skin and which cells are involved? To 
date the best-studied effects of EGF are its ability to increase 
the proliferation, differentiation, and even repair of various 
epithelia including skin (for review, see [2- 6]). Specific EGF 
receptors are found on both epithelial and nonepithelial cells, 
and in vitro nonepithelial cells respond to EGF. In human skin 
EGF receptors are found on keratinocytes, especially in the 
basal layer, sebocytes, smooth muscle cells including arrector 
pilorum muscles, and myoepithelial cells [22]. Since EGF re-
ceptors are found in high concentrations on normal cells that 
do not have a high proliferative capacity [22], the simple 
inference that EGF only stimulates cell growth or the presence 
of EGF receptors indicates dividing cells is not true. In fact, 
adding EGF to A-431 cells which have millions of EGF recep-
tors slows growth and proliferation. Interestingly, EGF is con-
tinuously present in all human body fluids including human 
sweat [4]. It is constantly available to modulate both rapid 
metabolic events and influence the growth, differentiation, 
and/or repair of skin. 
What does EGF do to cells and tissue? In mammalian skin 
EGF at the tissue and cellular level stimulates protein, RNA, 
and DNA synthesis (for review, see [2- 4]); increases uptake of 
nutrients including calcium [23] ; alters phospholipid metabo-
lism including phosphoinositol (PI) turnover [23,24] ; and in-
creases the release of arachidonic acid [1,25]. The stimulation 
of these processes by EG F is not unique and many other factors 
may control epidermal growth (for review, see [7]). Whether 
EGF and simi lar mitogens directly affect production of arach-
idonic acid and/or its metabolites is of great interest because it 
would provide insight into the mechanisms of growth, tumor 
promotion, inflammation, and even membrane transport and 
secretion. 
How does EGF affect prostaglandin synthesis? If EGF alters 
arachidonic acid release in its target cells, this effect should 
lead to a proportionate change in its metaboli tes assuming no 
alterations in the concentration and activity of rate-limiting 
enzymes. EGF may alter prostaglandin metabolism simply by 
modulating the amount or activity of cyclooxygenases or lipox-
ygenases. In fact, recent in vitro studies indicated that the 
synthesis of one of these enzymes capable of metabolizing 
arachidonic acid was directly affected by adding EGF. In aspi-
rin-inactivated cells, EGF induced rapid restoration of cycloox-
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ygenase synthesis in a cycloheximide-sensitive process which 
did not require new mRNA synthesis (26] . Since refractoriness 
to prostaglandin-releasing stimuli may develop due to inacti-
vation of cyclooxygenase, EGF may be involved in the rapid 
regeneration of prostaglandin synthetase in vivo. 
What is the relationship of EGF, phosphatidyl inositol turn-
over, and arachidonic acid release? In most tissues two major 
classes of ce ll membrane-linked receptor systems control cell 
proliferation and related cellular functions. The best-charac-
terized system is mediated by production of cyclic AMP from 
ade nylate cyclase which becomes activated by different ligands 
[27]. The less well-characterized system in which EGF is in-
volved activates PI turnover, Ca2+ mobilization, (cyclic GMP 
production?), and frequently release of arachidonic acid as 
s hown by Aoyagi et al [1). A strong correlation exists between 
rapid PI turnover and rapid cell proliferation [9] and the 
changes in PI metabolism due to mitogens such as EGF occur 
much earlier than any changes in DNA synthesis and related 
responses. Although often the primary enzyme thought to be 
involved in arachidonic acid release is phospholipase A2 [7], 
inositol phospholipids are a major source of arachidonic acid 
released in most cells [8). Therefore, any stimulation or inhi-
bition of the metabolism of PI should have major effects of 
arachidonic acid release. PI turnover such as that generated by 
EGF may be a signal-generating system producing intracellular 
second messengers and liberating arachidonic acid for further 
conversion to its active metabolites [8]. 
Does EGF-stimulated tyrosine kinase directly affect PI turn-
over? Whether EGF activates PI turnover indirectly by chang-
ing substrate availability or has a direct effect on these phos-
pholipids by the activated EGF tyrosine kinase is not currently 
known, i.e., does the EGF-stimulated tyrosine kinase act as an 
inositol lipid kinase? There is a precedent for suggesting such 
an EGF-stimulated phospholipid kinase activity . Some onco-
genes not only involve tyrosine kinases like EGF but also affect 
PI pathways by acting as inositol lipid kinases [9]. For example, 
Src pp60 u-src (9] phosphorylates phosphatidylinositol 4-phos-
phate and 1,2 diacylglycerol (DG), an important cofactor for 
the Ca2+, phospholipid (usually phosphatidyl-serine) depend-
ent protein kinase C [10]. DG is present in small amounts in 
membranes and is only transiently produced in response to 
certain membrane active ligands such as EGF [9]. Since the 
mammalian PI from wh ich DG is commonly produced contains 
arachidonic acid at position 2, reactions that control the rate 
of DG conversion back to PI or further degradation to arachi-
donic acid for prostaglandin synthesis may be very important 
[9,10]. 
Is EGF receptor phosphorylation by protein kinase C impor-
tant? What happens when Ca2+ and PI turnover is altered by 
EGF? EGF may help regulate its endogenous tyrosine kinase 
by promoting Ca2+ influx, PI turnover, protein kinase Cacti-
vation , and phosphorylation of receptor tyrosine kinase. In 
vitro EGF but not phorbol esters mediated increases in arach-
idonate release and prostaglandin E 2 synthesis required exter-
nal Ca2+ [25]. Tumor promoters such as tetradecanoylphorbol-
13-acetate (TPA) may produce their effects on the EGF recep-
tor by their almost irreversible activation of protein kinase C 
and decreasing its need for Ca2+ and DG [10,28-30]. TPA 
stimulated phosphorylation of the EGF receptor in the same 
sites as purified protein kinase C [11,28,29]. Therefore, the 
findings that protein kinase C is the major binding site for 
TPA and other active phorbol esters as well as mediating the 
actions of 3 chemically distinct tumor promoters [10,30] is 
exciting. The consequence of either TP A or protein kinase C 
phosphorylating the EGF receptor appears to be a decrease in 
its ability to autophosphorylate and inhibit EGF binding. 
How do cyclic nucleotides affect EGF metabolism? It must 
be emphasized that EGF is thought to produce its direct effects 
via the cyclic nucleotide independent tyrosine kinase. However, 
as discussed above, the EGF receptor can be phosphorylated 
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by protein kinase C which itself is subject to metabolic regula-
tion. For example, cyclic AMP and GMP do not directly antag-
onize each other in most cellular reactions but both inhibit 
receptor-linked PI turnover by inhibiting protein kinase C 
activation [10] . The interactions ofCa2+ metabolism, PI, cyclic 
nucleotides, and arachidonic acid metabolites due to activation 
of cell membrane receptors by growth factors, oncogenes, ad-
renergic agents, and tumor promoters with and by protein 
kinase C are clearly important. Therefore, the two major growth 
regulatory systems discussed above may interact through sub-
strates such as the well-defined EGF receptor-tyrosine kinase 
which are phosphorylated in a regulatory manner by protein 
kinase C. 
In summary, this editorial has sketchily indicated that future 
research in the following areas are likely to provide new insights 
into the normal and abnormal function of skin: EGF, Ca2+, 
arachidonic acid and its metabolites, protein kinase C, phos-
pholipid metabolism, cyclic nucleotides, polyamines ..... . . 
This list should sound familiar to all serious students of epi-
dermal growth control mechanisms as we have added only a 
few new bars of harmony to the same timeless melody. 
Lloyd E. King, Jr., M.D., Ph.D. 
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